METHOD FOR THE SELECTION OF ANTIBODIES AGAINST BCMA

An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APR...

Full description

Saved in:
Bibliographic Details
Main Authors FREIMOSER-GRUNDSCHOBER, Anne, BACAC, Marina, AST, Oliver, STREIN, Klaus, HOSSE, Ralf, Moser, Samuel, UMANA, Pablo, KLEIN, Christian, VU, Minh Diem, MOESSNER, Ekkehard, FAUTI, Tanja
Format Patent
LanguageEnglish
Published 09.08.2018
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES
MEASURING
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
TESTING
Online AccessGet full text

Cover

More Information
Summary:An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-κB activation, BAFF-dependent NF-κB activation, and does not alter NF-κB activation without BAFF and APRIL is useful as a therapeutic agent.
Bibliography:Application Number: US201815945554